In vivo effects by estrone sulfate on the central nervous system-senile dementia (Alzheimer's type).
Seven women with senile dementia-Alzheimer's type (SDAT) were treated with conjugated estrogen [main content: estrone sulfate (E1-S)], at a dose of 1.25 mg/day over a 6-week period. A New Screening Test for Dementia developed by Japanese National Institute of Mental Health (NS) and the scores of Hasegawa Scale for dementia (HS) were performed every 3 weeks. Six women showed improvements in NS (P less than 0.05) and 5 women showed improvements in HS. Untreated women with SDAT did not show any improvement. Serum E1-S was measured by a direct radioimmunoassay. Serum E1-S was 911 +/- 156 pg/ml in 7 women with SDAT and lower than that of 7 normal women (1020 +/- 216 pg/ml). Following the treatment, serum E1-S increased to a level of 21.1 +/- 8.1 ng/ml. Estrone and estradiol-17 beta also increased. The results suggest a possibility for the future clinical use of estrogen for senile dementia, after careful clinical research trials including the side effects.
Honjo
H
H
Department of Obstetrics and Gynecology, Kyoto Prefectural University of Medicine, Japan.
Ogino
Y
Y
Naitoh
K
K
Urabe
M
M
Kitawaki
J
J
Yasuda
J
J
Yamamoto
T
T
Ishihara
S
S
Okada
H
H
Yonezawa
T
T
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000188:drug therapy*; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use*; D004970:Estrone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D012016:Reference Values
D004966:Estrogens, Conjugated (USP); D004970:Estrone; C017296:estrone sulfate